Trial reportBMC medicine2025
Impact of antihypertensive drug classes on cardiovascular outcomes: insights from the STEP study.
Trial report in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03015311 (Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe optimal class of antihypertensive drugs for reducing cardiovascular risk remains unclear. This study investigated whether prolonged exposure to specific antihypertensive drug classes is associated with lower cardiovascular risk in individuals with well-controlled blood pressure.
methodsThis study utilised data from the STEP trial, which enrolled elderly, hypertensive Chinese patients with no history of stroke. After excluding 234 patients lost to follow-up and 20 patients without blood pressure records after randomisation, 8257 patients were included. The relative time on each antihypertensive drug (medication time/event time) was calculated. The primary outcome was a composite of the first occurrence of stroke, acute coronary syndrome (ACS), acute decompensated heart failure, coronary revascularisation, atrial fibrillation, and cardiovascular death. Secondary endpoints included individual components of the primary outcome. Cox regression analysis was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for each outcome.
resultsOver a median 3.34 years follow-up, primary outcome analysis revealed that longer relative exposure to angiotensin II receptor blockers (ARBs) or calcium channel blockers (CCBs) significantly reduced cardiovascular risk. Each unit increase in relative time on ARBs was associated with a 45% lower risk of the primary outcome (HR 0.55, 95% CI 0.43-0.70), whereas CCBs reduced risk by 30% (HR 0.70, 95% CI 0.54-0.92). Diuretics demonstrated neutral results. Conversely, longer relative time on beta-blockers was linked to a higher primary outcome risk (HR 2.20, 95% CI 1.81-2.68). Regarding secondary outcomes, extended exposure to both ARBs and CCBs was significantly associated with lower risks of all-cause and cardiovascular mortality. Longer exposure to ARBs produced additional benefits by reducing risks of stroke, ACS, and major adverse cardiac events (MACE). The HRs for ARBs per-unit increase in relative time remained consistently lower than those of CCBs across the primary outcome, MACE, and stroke (all P < 0.05).
conclusionsThis post hoc analysis suggested that ARBs and CCBs might be more favourable for composite cardiovascular outcomes than diuretics and beta-blockers. ARBs appeared to offer greater cardiovascular benefits than CCBs. Longer exposure to beta-blockers was associated with a higher cardiovascular risk, which might reflect a selection bias based on medical indications.
trial registrationSTEP ClinicalTrials.gov number, NCT03015311. Registered 2 January 2017.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.